All countries, N = 19,601 | Total | Austria | Belgium | Estonia | France | Germany | Ireland | Latvia | Lithuania | Netherlands | Norway | Portugal | Slovenia | Spain | Sweden | p-valueb |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | 19,601 | 1356 | 885 | 969 | 1876 | 2565 | 923 | 1386 | 511 | 758 | 1126 | 2345 | 1144 | 2826 | 931 | |
Cancer | 53% | 55% | 60% | 43% | 72% | 65% | 60% | 26% | 41% | 60% | 48% | 45% | 39% | 56% | 52% | < 0.001 |
Heart disease | 68% | 70% | 76% | 77% | 82% | 77% | 68% | 69% | 73% | 67% | 56% | 50% | 56% | 66% | 68% | < 0.001 |
Liver disease | 90% | 96% | 89% | 93% | 89% | 95% | 93% | 89% | 90% | 92% | 89% | 81% | 91% | 87% | 93% | < 0.001 |
Respiratory disease | 11% | 8% | 10% | 14% | 16% | 13% | 19% | 8% | 10% | 11% | 5% | 11% | 8% | 14% | 6% | < 0.001 |
Don’t know | 5% | 2% | 4% | 5% | 4% | 2% | 5% | 6% | 2% | 6% | 9% | 9% | 6% | 7% | 4% | < 0.001 |
None | 2% | 1% | 1% | 1% | 1% | 2% | 0% | 2% | 4% | 1% | 1% | 4% | 2% | 1% | 2% | < 0.001 |
Female breast cancer* | 15% | 15% | 17% | 13% | 24% | 24% | 28% | 7% | 13% | 23% | 10% | 7% | 9% | 13% | 15% | < 0.001 |
Liver cancer* | 50% | 51% | 57% | 41% | 69% | 62% | 58% | 25% | 39% | 56% | 42% | 43% | 37% | 53% | 47% | < 0.001 |
Colon cancer* | 39% | 44% | 47% | 29% | 55% | 53% | 44% | 20% | 28% | 46% | 34% | 23% | 30% | 39% | 38% | < 0.001 |
Oral cancer* | 28% | 28% | 35% | 18% | 44% | 41% | 36% | 10% | 19% | 33% | 15% | 21% | 25% | 28% | 20% | < 0.001 |
Skin cancer* | 6% | 6% | 5% | 6% | 12% | 9% | 7% | 3% | 6% | 7% | 2% | 3% | 2% | 6% | 3% | < 0.001 |
Don’t know* | 2% | 2% | 1% | 2% | 2% | 2% | 1% | 1% | 1% | 2% | 3% | 1% | 1% | 1% | 4% | < 0.001 |
None* | 0% | 0% | 0% | 0% | 0% | 0% | 1% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | < 0.001 |